Suppliers / Acs Dobfar

Acs Dobfar

Italy Updated 9 July 2026

Acs Dobfar is an API and finished-dose manufacturer based in Italy. It holds 160 active US drug master files and 18 valid CEPs. Its filings concentrate with DIGEMAPS (DO), US FDA and MINSA (CR). Its GMP standing is certified by EMA, ANVISA (Brazil) and MFDS (Korea), among 5 authorities. Its most recent recorded inspection, by US FDA, closed on 23 November 2023 as VAI.

160
active US DMFs
18
valid CEPs
12
registered plants
116
filings across 12 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
0 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 23 November 2023 VAI US FDA
  • 27 October 2023 VAI US FDA
  • 26 May 2023 VAI US FDA
  • 16 May 2023 VAI US FDA
  • 14 October 2022 VAI US FDA
  • 23 September 2022 VAI US FDA
  • 8 April 2022 VAI US FDA
  • 3 December 2021 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Teramo, United Arab Emirates Not on file
Verona, United Arab Emirates Not on file
Pomezia, United Arab Emirates Not on file
POMEZIA (RM), Italy Not on file
CASTELLALTO, Italy Not on file
SAN GIULIANO MILANESE, Italy Not on file

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Meropenem SFDA (Saudi Arabia), US FDA 15
Ceftazidime EDQM, US FDA 13
Ceftriaxone EDQM, SFDA (Saudi Arabia), US FDA 11
Imipenem SFDA (Saudi Arabia), US FDA 10
Cefotaxime EDQM, US FDA 9
Cefuroxime SFDA (Saudi Arabia), US FDA 9
Amikacin US FDA 8
Ampicillin US FDA 8
Cefapirin US FDA 8
Cefoxitin US FDA 8
Show all 30 molecules on file
Nafcillin US FDA 8
Clindamycin EDQM, SFDA (Saudi Arabia), US FDA 7
Cefaclor EDQM, US FDA 6
Cilastatin SFDA (Saudi Arabia), US FDA 6
Cefazolin EDQM, US FDA 5
Cephalexin EDQM, US FDA 5
Cefadroxil US FDA 4
Cefalotin US FDA 4
Cefepime US FDA 4
Cefotetan US FDA 4
Ceftaroline Fosamil US FDA 4
Ceftibuten US FDA 4
Ertapenem US FDA 4
Gentamicin US FDA 4
Piperacillin US FDA 4
Sulbactam US FDA 4
Tazobactam US FDA 4
Cefalexin Monohydrate EDQM 2
Amoxicillin Sodium EDQM 1
Ampicillin Sodium EDQM 1

Also appears on these molecule pages

Show 1 more molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
DIGEMAPS (DO) 33 None
US FDA 20 4
MINSA (CR) 13 None
INVIMA (CO) 12 None
ARCSA (EC) 10 None
Health Canada 7 None
EMA None 11
ANVISA (Brazil) None 8
MFDS (Korea) None 6
NAFDAC (NG) None 1

Comparing suppliers?

Choose your molecules and target markets. Acs Dobfar comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 23 November 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates